EMA Authorised: Tovanor Breezhaler (glycopyrronium bromide) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Tovanor Breezhaler, a glycopyrronium bromide inhalation product for chronic obstructive pulmonary disease, with Novartis Europharm Limited as the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Tovanor Breezhaler (glycopyrronium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Limited. Decision date: 23/01/2026